Terminated PHASE3 NCT03202446

Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer

Phase 3 Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT) System in Advanced Breast Cancer

Sponsor: Eske Corporation S.A.C

Conditions Breast Cancer Stage IIIA Breast Cancer Stage IV Breast Cancer, Stage IIIB

Interventions 1% Glycated Chitosan Cyclophosphamide Photothermal Laser Placebo Standard of Care

Updated 6 times since 2017 Last updated: Feb 22, 2018 Started: Jun 13, 2016 Primary completion: Jan 31, 2018 Completion: Jan 31, 2018

This PHASE3 trial investigates Breast Cancer Stage IIIA and Breast Cancer Stage IV and is currently terminated or withdrawn. Eske Corporation S.A.C leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Mar 2018 — Jun 2018 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated

▶ Show 1 earlier version

Jul 2017 — Mar 2018 [monthly]

Recruiting PHASE3

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eske Corporation S.A.C

Data source: Eske Corporation S.A.C

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lima, Peru